

Lévis, May 28, 2018

BY EMAIL

Ms. Kathryn Nijssen
Initiatives Manager
Canadian Clinical Trials Coordinating Centre
200-119 Ross Avenue,
Ottawa, ON K1Y 0N6

Subject: Use of Model Clinical Trial Agreement

Dear Ms. Nijssen,


Our organization has reviewed the current version of the mCTA and would like to notify CCTCC and our Canadian clinical trial stakeholder community of the following:

1. We will offer and/or accept use of the mCTA for phase II and III industry sponsored clinical trials.
2. We agree to the CCTCC listing our organization as one using the mCTA and the CCTCC maintaining our contact information to facilitate ongoing mCTA initiative communications.
3. We agree to compile data on our use of the mCTA using the decided metrics and provide them to the CCTCC on an annual basis for aggregation with data from all other users and metrics reporting by CCTCC to clinical trial stakeholders.
4. We agree to suggest to the CCTCC mCTA changes (if any) on an annual basis and to participate with clinical trial stakeholders in an annual consultation about creation of subsequent mCTA versions.
5. We reserve the right at any time to notify CCTCC if we cease to use the mCTA (Current or subsequent versions) and CCTCC agrees to remove our organization from mCTA user lists.

Yours sincerely,



Véronique Boutier
Directrice administrative de la recherche



Stéphane Langlois
Directeur des ressources financières et de l'approvisionnement